로딩 중…
지수 로딩 중…
Niagen Bioscience Inc
NAGE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$2.99+0.00%
2026-09-18
Financials
Valuation Metrics
Niagen Bioscience Inc's Market Cap is $238M. At end of 2025 it was $502M. Ranked #2994 of 3,121 in US market (top 96%), #1362 of 1,463 on NASDAQ (top 93%), #248 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $238M | US#2,994/3,121 Sec#248/266 |
| Revenue | $129M | US#2,657/3,121 Sec#119/266 |
| Net Income | $16M | US#2,125/3,121 Sec#67/266 |
| Total Assets | $107M | US#3,060/3,121 Sec#262/266 |
| Net Assets | $83M | US#2,828/3,121 Sec#218/266 |
| Employees | 117 | US#2,597/3,121 Sec#167/266 |
| Value | ||
| P/E | 14.89x | US#772/3,121 Sec#20/266 |
| P/B | 2.89x | US#1,707/3,121 Sec#84/266 |
| P/S | 1.84x | US#1,220/3,121 Sec#23/266 |
| EV/EBITDA | 9.40x | US#713/3,121 Sec#21/266 |
| FCF Yield | 2.38% | US#1,961/3,121 Sec#65/266 |
| Profitability | ||
| ROE | 19.38% | US#616/3,121 Sec#32/266 |
| ROA | 15.00% | US#225/3,121 Sec#25/266 |
| Op. Margin | 6.67% | US#1,866/3,121 Sec#69/266 |
| Revenue Growth | 10.99% | US#1,188/3,121 Sec#94/266 |
| Earnings Growth | -9.80% | US#1,450/3,121 Sec#38/266 |
| Financial Health | ||
| Debt Ratio | 29.16% | US#324/3,121 Sec#103/266 |
| Total Debt | $2M | US#2,957/3,121 Sec#234/266 |
| FCF | $6M | US#2,265/3,121 Sec#84/266 |
| Cash | $67M | US#2,449/3,121 Sec#208/266 |
| Current Ratio | 6.50x | US#377/3,121 Sec#119/266 |
| Net Debt/EBITDA | -3.49x | US#99/3,121 Sec#7/266 |
| Performance | ||
| 1Y Return | -70.51% | US#3,067/3,121 Sec#259/266 |
| 1M Return | -5.68% | US#1,258/3,121 Sec#115/266 |
| From 52W High | -71.58% | US#3,028/3,121 Sec#245/266 |
| 1Y MDD | -71.09% | US#2,977/3,121 Sec#239/266 |
| Trading | ||
| Volume | 460,645 shares | US#2,623/3,121 Sec#252/266 |
| Trading Value | $1M | US#3,055/3,121 Sec#259/266 |
| Per Share | ||
| EPS | $0.20 | US#2,034/3,121 Sec#66/266 |
| BPS | $1.04 | US#2,695/3,121 Sec#204/266 |
Company Info
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.